bone marrow neoplasms

Summary

Summary: Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.

Top Publications

  1. ncbi Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy
    Kacper Jankowski
    Stem Cell Biology Program, James Graham Brown Cancer Center, University of Louisville, 529 South Jackson Street, Louisville, KY 40202, USA
    Cancer Res 63:7926-35. 2003
  2. ncbi Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype
    Marija Balic
    Department of Pathology, Keck School of Medicine, University of Southern California, 2011 Zonal Avenue, Los Angeles, CA 90033, USA
    Clin Cancer Res 12:5615-21. 2006
  3. ncbi A pooled analysis of bone marrow micrometastasis in breast cancer
    Stephan Braun
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    N Engl J Med 353:793-802. 2005
  4. ncbi Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated
    I Funke
    Department of Surgery, University of Munich, Germany
    J Clin Oncol 16:557-66. 1998
  5. ncbi Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients
    Kjersti Flatmark
    Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway
    Clin Cancer Res 8:444-9. 2002
  6. ncbi Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years
    Martin J Slade
    Department of Cancer Cell Biology, Division of Medicine, Imperial College, London, United Kingdom
    Int J Cancer 114:94-100. 2005
  7. pmc Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer
    I H Benoy
    Translational Cancer Research Group Antwerp, Department of Pathology University of Antwerp University Hospital Antwerp, Edegem 2650, Belgium
    Br J Cancer 94:672-80. 2006
  8. ncbi Detection and clinical importance of micrometastatic disease
    K Pantel
    K Pantel, Universitatsfrauenklinik, Universitätsklinikum Eppendorf, Hamburg, Germany
    J Natl Cancer Inst 91:1113-24. 1999
  9. ncbi Microangiopathic hemolytic anemia (MAHA) as paraneoplastic syndrome in metastasized signet ring cell carcinomas: case reports and review of the literature
    H T Arkenau
    Klinik fur Innere Medizin, Klinikum Bremen Ost, Bremen, Germany
    Z Gastroenterol 43:719-22. 2005
  10. ncbi Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment
    Jens Kollermann
    Institute of Pathology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Clin Oncol 26:4928-33. 2008

Research Grants

  1. Molecular Detection of Occult Neuroblastoma
    Irene Cheung; Fiscal Year: 2004
  2. A novel set of molecular markers to measure metastatic neuroblastoma
    Nai Kong Cheung; Fiscal Year: 2007
  3. Beta glucan enhances antibody therapy for neuroblastoma
    Nai Kong Cheung; Fiscal Year: 2003
  4. Cell-based tumor vaccines targeting CD4+ T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2010
  5. Tumor cell antigen presentation to CD4 + T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2004
  6. CELL BASED TUMOR VACCINES TARGETING CD4+ T LUMPHOCYTES
    Suzanne Ostrand Rosenberg; Fiscal Year: 2003
  7. Tumor cell antigen presentation to CD4 + T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2003
  8. CELL BASED TUMOR VACCINES TARGETING CD4+ T LUMPHOCYTES
    Suzanne Ostrand Rosenberg; Fiscal Year: 2002
  9. Tumor cell antigen presentation to CD4 + T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2002
  10. Tumor-induced immune suppression.
    Suzanne Ostrand Rosenberg; Fiscal Year: 2009

Detail Information

Publications164 found, 100 shown here

  1. ncbi Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy
    Kacper Jankowski
    Stem Cell Biology Program, James Graham Brown Cancer Center, University of Louisville, 529 South Jackson Street, Louisville, KY 40202, USA
    Cancer Res 63:7926-35. 2003
    ..Signaling from the c-MET receptor may also contribute to the resistance of RMS cells to conventional treatment modalities...
  2. ncbi Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype
    Marija Balic
    Department of Pathology, Keck School of Medicine, University of Southern California, 2011 Zonal Avenue, Los Angeles, CA 90033, USA
    Clin Cancer Res 12:5615-21. 2006
    ..Recognizing the potential effect of prevalence of putative stem cells among DTC, we evaluated the bone marrow DTC...
  3. ncbi A pooled analysis of bone marrow micrometastasis in breast cancer
    Stephan Braun
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    N Engl J Med 353:793-802. 2005
    ..We assessed the prognostic significance of the presence of micrometastasis in the bone marrow at the time of diagnosis of breast cancer by means of a pooled analysis...
  4. ncbi Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated
    I Funke
    Department of Surgery, University of Munich, Germany
    J Clin Oncol 16:557-66. 1998
    ..In the present meta-analyses, 20 studies, which included 2,494 patients, regarding the prognostic influence of a positive bone marrow micrometastases (BMM) status on relapse-free and/or overall survival were analyzed...
  5. ncbi Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients
    Kjersti Flatmark
    Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway
    Clin Cancer Res 8:444-9. 2002
    ..Furthermore, that screening of 2 x 10(7) MNCs in a BM sample can be completed in <3 h makes the method an attractive alternative to other techniques...
  6. ncbi Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years
    Martin J Slade
    Department of Cancer Cell Biology, Division of Medicine, Imperial College, London, United Kingdom
    Int J Cancer 114:94-100. 2005
    ..These results indicate that MRD persists despite adjuvant therapy in a majority of patients with primary breast cancer up to 4 years following surgery...
  7. pmc Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer
    I H Benoy
    Translational Cancer Research Group Antwerp, Department of Pathology University of Antwerp University Hospital Antwerp, Edegem 2650, Belgium
    Br J Cancer 94:672-80. 2006
    ..The use of either larger volumes of PB or performing an enrichment step for circulating tumour in blood cells might improve these results...
  8. ncbi Detection and clinical importance of micrometastatic disease
    K Pantel
    K Pantel, Universitatsfrauenklinik, Universitätsklinikum Eppendorf, Hamburg, Germany
    J Natl Cancer Inst 91:1113-24. 1999
    ....
  9. ncbi Microangiopathic hemolytic anemia (MAHA) as paraneoplastic syndrome in metastasized signet ring cell carcinomas: case reports and review of the literature
    H T Arkenau
    Klinik fur Innere Medizin, Klinikum Bremen Ost, Bremen, Germany
    Z Gastroenterol 43:719-22. 2005
    ..Parallel to symptomatic treatment we started chemotherapy treatment (ELF and PLF regimen, respectively). In both cases we were able to control the MAHA and cancer progression...
  10. ncbi Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment
    Jens Kollermann
    Institute of Pathology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Clin Oncol 26:4928-33. 2008
    ..To explore whether the presence of occult disseminated tumor cells (DTCs) in the bone marrow before neoadjuvant hormone therapy influences the prognosis of patients with organ confined prostate cancer treated by radical prostatectomy...
  11. doi Thrombotic thrombocytopenic purpura as the first manifestation of metastatic adenocarcinoma in a young woman
    Gurhan Kadikoylu
    Adnan Menderes University Medical Faculty, Division of Hematology, 09100 Aydin, Turkey
    Transfus Apher Sci 42:39-42. 2010
    ..In conclusion, malignancy and bone marrow involvement should be considered when associated with leukoerythroblastic picture and TTP...
  12. ncbi ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients
    S Braun
    Frauenklinik and Poliklinik, Klinikum rechts der Isar, Technische Universitat, Munchen, Germany
    Cancer Res 61:1890-5. 2001
    ..78 (95% confidence interval, 1.11-6.96) for overall survival (P = 0.029). We therefore conclude that erbB2 overexpression characterizes a clinically relevant subset of breast cancer micrometastases...
  13. doi Evaluation of a RT-PCR based routine screening tool for the detection of disseminated epithelial cells in the bone marrow of breast cancer patients
    Sven Becker
    Department of Gynaecology and Obstetrics, University Hospital Tuebingen, Calwerstrasse 7, 72076 Tuebingen, Germany
    Breast Cancer Res Treat 117:227-33. 2009
    ..Immunocytochemistry (ICC) remains the gold standard for their detection. While assays based on RT-PCR are available, they have not been used for routine detection of DTC's...
  14. pmc Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer
    I H Benoy
    Translational Cancer Research Group Antwerp, Lab Pathology University of Antwerp University Hospital Antwerp, 2650 Edegem, Belgium
    Br J Cancer 91:1813-20. 2004
    ....
  15. pmc Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer
    Ina H Benoy
    Translational Cancer Research Group Antwerp, Laboratory of Pathology, University of Antwerp University Hospital Antwerp, Edegem, Belgium
    Breast Cancer Res 7:R210-9. 2005
    ....
  16. ncbi Neovascularization of bone marrow in patients with diffuse multiple myeloma: a correlative study of magnetic resonance imaging and histopathologic findings
    Andrea Baur
    Department of Clinical Radiology, University of Munich Grosshadern, Munich, Germany
    Cancer 101:2599-604. 2004
    ..The goal of the current study was to assess the correlation between bone marrow histology and contrast enhancement in infiltrative diffuse myeloma...
  17. ncbi Detection of malignant bone marrow involvement with dynamic contrast-enhanced magnetic resonance imaging
    L A Moulopoulos
    Department of Radiology, Medical School, University of Athens, Athens, Greece
    Ann Oncol 14:152-8. 2003
    ..The purpose of this study was to evaluate the role of dynamic contrast-enhanced magnetic resonance imaging (dMRI) in detecting bone marrow involvement in cancer patients...
  18. ncbi Prognostic significance of bone marrow micrometastases in patients with gastric cancer
    K W Jauch
    Department of Surgery, Ludwig Maximilians University, Munich, Germany
    J Clin Oncol 14:1810-7. 1996
    ..The aim of this study was to examine the prognostic relevance of these cells in patients with gastric cancer and to evaluate by multivariate analysis their predictive value compared with conventional risk factors...
  19. ncbi Clinical significance of occult metastatic cells in bone marrow of breast cancer patients
    S Braun
    Frauenklinik und Poliklinik, , Klinikum rechts der Isar, , Germany
    Oncologist 6:125-32. 2001
    ..The present review summarizes the current data on the clinical significance of occult metastatic breast cancer cells in bone marrow...
  20. ncbi Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer
    Ina H Benoy
    Translational Cancer Research Group Antwerp, Wilrijk, Belgium
    Clin Breast Cancer 7:146-52. 2006
    ..Bone marrow samples from a large cohort of patients with breast cancer were analyzed for the presence of DTC by immunocytochemistry (ICC) or a molecular-based method...
  21. ncbi Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity
    Volkmar Muller
    Institute of Tumor Biology, Clinic of Gynecology, Institute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Clin Cancer Res 11:3678-85. 2005
    ....
  22. ncbi The clinical significance of disseminated tumor cells in breast cancer
    Martin J Slade
    Department of Oncology, Imperial College of Science, Technology and Medicine, 5th Floor MRC Cyclotron Building, Du Cane Road, London W12 0NN, UK
    Nat Clin Pract Oncol 4:30-41. 2007
    ....
  23. ncbi Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow
    S Braun
    I Frauenklinik, Klinikum Innenstsdt, Ludwig Maximilians Universitat, Munich, Germany
    Clin Cancer Res 5:3999-4004. 1999
    ..Selection of EpCAM-/ CK+ tumor clones showed that further antibodies directed against tumor-associated antigens are warranted to improve the efficacy of monospecific approaches...
  24. ncbi Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer
    Jussuf T Kaifi
    Klinik fuer Allgemein, Viszeral und Thoraxchirurgie, Universitaetsklinikum Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    J Natl Cancer Inst 97:1840-7. 2005
    ..We investigated CXCR4 expression in esophageal cancer specimens and its association with survival, lymph node microinvolvement, and bone marrow micrometastasis...
  25. ncbi Molecular signature associated with bone marrow micrometastasis in human breast cancer
    Ute Woelfle
    Institute of Tumor Biology, University Hospital Hamburg Eppendorf, Germany
    Cancer Res 63:5679-84. 2003
    ..Thus, BM micrometastasis is a selective process with a specific molecular signature of the primary tumor...
  26. ncbi Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy
    Sven Becker
    Department of Gynecology and Obstetrics, University Hospital Tubingen, Tubingen, Germany
    Breast Cancer Res Treat 97:91-6. 2006
    ..020). Adjuvant treatment regimens are not able to completely eliminate cytokeratin-positive cells from the bone marrow. Prospective studies need to evaluate, whether these cells could become targets for additional adjuvant therapy...
  27. ncbi Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy
    S Braun
    I Frauenklinik and Department of Gynecological Pathology, Klinikum Innenstadt, Ludwig Maximilians University, Munchen, Gemany
    J Clin Oncol 19:1468-75. 2001
    ..In the present study we analyzed whether a correlation exists between microscopic tumor cell spread to bone marrow and to lymph nodes and attempted to determine which route is clinically more important...
  28. ncbi Immunomagnetic enrichment and detection of micrometastases in colorectal cancer: correlation with established clinical parameters
    Martin R Weihrauch
    Department of Internal Medicine I, University of Cologne, Germany
    J Clin Oncol 20:4338-43. 2002
    ..We used magnetic activated cell sorting (MACS), a highly sensitive method, to increase detection rates and correlated the presence of cytokeratin (CK)-expressing cells with clinical parameters...
  29. pmc HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
    A Vincent-Salomon
    Department of Tumor Biology, Institut Curie, Paris, France
    Br J Cancer 96:654-9. 2007
    ..Therefore, the efficiency of anti-HER2 adjuvant therapy could be evaluated, in a clinical trial, by sequential detection of HER2-positive micrometastatic cells within the bone marrow, before and after treatment...
  30. ncbi Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia
    L Bonavina
    Department of General and Oncologic Surgery, University of Milan, Italy
    Surgery 129:15-22. 2001
    ..However, the prognostic and therapeutic implications of this finding need further investigation...
  31. ncbi Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR
    N Berois
    Laboratorio de Oncología Básica, Depto de Bioquimica, Facultad de Medicina, Av Gral Flores 2125, Montevideo CP 11800, Uruguay
    Eur J Cancer 36:717-23. 2000
    ..Our results suggest that CK19 and CEA RT-PCR assays are powerful methods for detecting disseminated breast cancer cells. A larger study with long-term follow-up is required in order to clarify their clinical usefulness...
  32. ncbi Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma
    Fabio Bozzi
    Department of Anatomic Pathology, Experimental Molecular Pathology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Anticancer Res 28:1565-9. 2008
    ..Myogenin (Myf4), a specific molecular RMS marker, was also investigated in the same samples. Since neuroblastoma (NB) metastasizes to the BM, the potential application of cytometry in differential diagnosis was explored...
  33. pmc Diagnostic cues for natural killer cell lymphoma: primary nodal presentation and the role of in situ hybridisation for Epstein-Barr virus encoded early small RNA in detecting occult bone marrow involvement
    C S Chim
    University Department of Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong, China
    J Clin Pathol 58:443-5. 2005
    ..This was resolved by in situ hybridisation for Epstein-Barr virus encoded small RNA, which detected occult bone marrow infiltration...
  34. ncbi Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy?
    S T Lim
    Department of Medical Oncology, National Cancer Centre, 11 Hospital Drive, 169610 Singapore
    Ann Oncol 16:215-8. 2005
    ..Although BM biopsy is a safe procedure, it is often poorly tolerated. This analysis aims to assess the incidence of BM involvement and to identify parameters predicting BM involvement in early-stage DLBCL...
  35. ncbi Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
    C Schindlbeck
    I Frauenklinik, Klinikum der Ludwig Maximilians Universität, Maistrasse 11, 80337 Munich, Germany
    J Cancer Res Clin Oncol 131:539-46. 2005
    ....
  36. ncbi Analysis of sensitivity and specificity of cytokeratin 19 reverse transcriptase/polymerase chain reaction for detection of occult breast cancer in bone marrow and leukapheresis products
    X Y Zhong
    Department of Obstetrics and Gynaecology, University Hospital, Heidelberg, Germany
    J Cancer Res Clin Oncol 125:286-91. 1999
    ..The work aimed to evaluate the sensitivity and specificity of the cytokeratin (CK) 19 reverse transcriptase/polymerase chain reaction (RT-PCR) for the detection of occult breast cancer in bone marrow and leukapheresis products...
  37. ncbi Detection of cancer cells disseminated in bone marrow using real-time quantitative RT-PCR of CEA, CK19, and CK20 mRNA in patients with gastric cancer
    Yasuki Fujita
    Department of Surgery 1, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960 1295, Japan
    Gastric Cancer 9:308-14. 2006
    ....
  38. ncbi Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer
    B Passlick
    Department of Surgery, Klinikum Innenstadt, University of Munich, Germany
    Ann Thorac Surg 68:2053-8. 1999
    ..The clinical relevance of this minimal hematogenous tumor cell dissemination is under vigorous debate...
  39. ncbi Bone marrow micrometastasis in breast cancer
    S Ozbas
    Department of General Surgery, Adnan Menderes University, Aydin, Turkey
    Br J Surg 90:290-301. 2003
    ..Several studies have demonstrated that bone marrow micrometastasis in patients with breast cancer is an independent prognostic factor for systemic recurrence and poorer survival...
  40. ncbi Sensitive detection of micrometastases in bone marrow from patients with breast cancer using immunomagnetic isolation of tumor cells in combination with reverse transcriptase/polymerase chain reaction for cytokeratin-19
    X Y Zhong
    Department of Obstetrics and Gynaecology, University Hospital, Heidelberg, Germany
    J Cancer Res Clin Oncol 126:212-8. 2000
    ..For the early diagnosis of disseminating disease, this assay is more efficient than RT-PCR alone and routine immunocytochemistry...
  41. ncbi Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow
    C Schindlbeck
    I Frauenklinik, Klinikum Ludwig Maximilians University, Munich, Germany
    Breast Cancer Res Treat 87:65-74. 2004
    ..The direct identification of HER2 on ITC-BM is the aim of ongoing research, potentially synergizing the prognostic relevance of ITC-BM and the predictive value of the HER2 status...
  42. pmc Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas
    Christian Schindlbeck
    1st Department of Obstetrics and Gynecology Klinikum, Ludwig Maximilians University, D 80337 Munich, Germany
    Breast Cancer Res 7:R1174-85. 2005
    ..We therefore examined 'tissue micro arrays' (TMAs) of 265 primary breast carcinomas from patients with known bone marrow (BM) status for HER2, Topoisomerase IIalpha (Top IIa), Ki 67, and p53...
  43. ncbi Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method
    B Naume
    Department of Oncology, The Norwegian Radium Hospital, University of Oslo, Montebello, Oslo, Norway
    Cytotherapy 6:244-52. 2004
    ....
  44. ncbi Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer
    F Janku
    Department of Oncology, Charles University Prague, 1st Faculty of Medicine, General Teaching Hospital, 128 08, Czech Republic
    Neoplasma 51:204-8. 2004
    ..RT-PCR assay for mammaglobin A may be a useful tool for detection of occult breast cancer cells in the bone marrow. Clinical and prognostic relevance of minimal residual disease should be further investigated...
  45. ncbi Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients
    Ute Woelfle
    Institute of Tumour Biology, Center of Experimental Medicine, University Hospital Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    J Immunol Methods 300:136-45. 2005
    ..The method described offers an excellent tool for the enrichment of micrometastatic tumour cell clusters; these clusters may represent the initial stage of development from a single disseminated tumour cell towards an overt metastasis...
  46. ncbi Bone marrow micrometastases and markers of angiogenesis in esophageal cancer
    Gary M Spence
    Department of Thoracic Surgery, Royal Victoria Hospital, Belfast, Northern Ireland
    Ann Thorac Surg 78:1944-9; discussion 1950. 2004
    ..We aim to establish if the detection of bone marrow micrometastases associates with elevated markers of angiogenesis and adverse histopathologic features of esophageal cancer...
  47. ncbi Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen
    Christian Schindlbeck
    First Department of Obstetrics and Gynecology, Ludwig Maximilians University of Munich, Maistrasse 11, 80337, Munich, Germany
    Histochem Cell Biol 123:631-7. 2005
    ..As TF is a specific marker of DTC-BM, it could be used as a target for antibody based therapy and immunomagnetic enrichment techniques for the isolation of DTC-BM...
  48. pmc How we process trephine biopsy specimens: epoxy resin embedded bone marrow biopsies
    T Krenacs
    Laboratory of Tumour Pathology and Molecular Diagnostics, Institute for Biotechnology, Bay Zoltan Foundation for Applied Research, H 6726 Szeged, Derkovits fasor 2, Hungary
    J Clin Pathol 58:897-903. 2005
    ..By meeting traditional and contemporary demands on the haematopathologist, it offers a powerful alternative to paraffin wax processing for diagnosis and research...
  49. ncbi Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer
    M Bregni
    Division of Hematology Bone Marrow Transplantation, Department of Oncology, Hematology Bone Marrow Transplantation Unit, and Blood Bank Tissue Typing Laboratory, Istituto Scientifico H San Raffaele, Milan, Italy
    Bone Marrow Transplant 37:311-5. 2006
    ..Although preliminary, these data suggest that a graft-versus-breast cancer effect is detectable on micrometastatic BM disease...
  50. ncbi A relevant immunomagnetic assay to detect and characterize epithelial cell adhesion molecule-positive cells in bone marrow from patients with breast carcinoma: immunomagnetic purification of micrometastases
    Valerie Choesmel
    UMR144 CNRS, Research Division, Institut Curie, Paris, France
    Cancer 101:693-703. 2004
    ..In this study, the authors assessed and improved the current methods for purifying and characterizing rare disseminated carcinoma cells...
  51. ncbi [A new approach for discovering minimal residual disease in patients with operable breast cancer]
    I Iovchev
    Khirurgiia (Sofiia) 59:19-22. 2003
    ..By immunochistochemistry method in the diagnostics of minimal residual disease in patients with breast cancer, more precise staging is achieved. This will change the therapeutic approach to these patients...
  52. ncbi Comparison of relative value of bone marrow aspirates and bone marrow trephine biopsies in the diagnosis of solid tumor metastasis and Hodgkin lymphoma: institutional experience and literature review
    Farah Moid
    Department of Pathology, George Washington University Hospital, Washington, DC 20037, USA
    Arch Pathol Lab Med 129:497-501. 2005
    ..Numerous reports differ in the relative value of these 2 procedures and fail to provide concise guidelines that can help choose the appropriate technique in this clinical situation...
  53. ncbi [Detection of minimal residual disease in children with neuroblastoma]
    B De Moerloose
    UZ Gent, Kliniek voor Kinderziekten C Hooft, Afdeling pediatrische hematologie oncologie, Faculteit Geneeskunde en Gezondheidswetenschappen UGent, De Pintelaan 185 B 9000 Gent
    Verh K Acad Geneeskd Belg 67:33-44. 2005
    ..Current multicenter trials in neuroblastoma trying to elucidate the relevance of residual cells at different time point during treatment are ongoing and will ultimately result in a consensus about this intruiging prognostic paramater...
  54. ncbi Can MIBG scan replace the need for bone marrow assessment at diagnosis and reassessment in stage 4 neuroblastomas?
    D Frappaz
    Department of Padiatrics, Centre Leon Berard, Lyon 69373, France
    Bull Cancer 91:E253-60. 2004
    ..However the correlation between bone marrow invasion and uptake of MIBG at metastatic sites remains unclear. This study investigates whether MIBG alone is sufficiently sensitive to make these procedures redundant...
  55. ncbi Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy
    A Schneeweiss
    University of Heidelberg, Department of Gynecology and Obstetrics, Heidelberg, Germany
    Ann Oncol 15:1627-32. 2004
    ..To determine the impact of micrometastatic bone marrow cells (MMC) on survival in high-risk primary breast cancer (HRPBC) patients treated with high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT)...
  56. ncbi [Bone marrow infiltration in B-cell non-Hodgkin's lymphomas: comparison between flow cytometry and bone marrow biopsy]
    Giovanni Carulli
    Divisione di Ematologia, Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina, Universita, Ospedale S Chiara, Pisa
    Recenti Prog Med 96:284-90. 2005
    ..These results show that a more complex analysis of bone marrow is needed to diagnose bone marrow infiltration, particularly in samples with minimal residual disease...
  57. ncbi CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases
    Heidi V Russell
    Texas Children s Cancer Center and Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
    J Pediatr Surg 39:1506-11. 2004
    ..The goal of this study was to investigate whether the degree of expression of CXCR4 on cells from neuroblastoma primary tumors was related to the pattern of metastatic involvement...
  58. ncbi Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer
    A Marilyn Leitch
    Department of Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9155, USA
    Am J Surg 190:539-42. 2005
    ..This report elucidates factors influencing patient accrual...
  59. ncbi The value of bone marrow aspirates culture for the detection of bone marrow micrometastasis in breast cancer
    W T Y Loo
    Department of Surgery, University of Hong Kong Medical Center, Queen Mary Hospital, China
    Biomed Pharmacother 59:S384-6. 2005
    ....
  60. ncbi [Detection of disseminated tumor cells in bone marrow--currently of no practical therapeutic value]
    N Ditsch
    Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Klinikum Grosshadern, LMU Munchen
    MMW Fortschr Med 144:37-9. 2002
    ..Against this background it is too early to say whether the detection of disseminated tumour cells in the bone marrow can be used as a prognostic factor with an impact on therapeutic strategies...
  61. doi Clinical outcome of gastric cancer patients with bone marrow metastases
    Hyo Song Kim
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Oncology 73:192-7. 2007
    ..We conducted a retrospective analysis to evaluate clinical manifestations and prognosis of gastric cancer patients with bone marrow metastases...
  62. ncbi Detection of micrometastatic cells in breast cancer by RT-pCR for the mammaglobin gene
    Patrizia Bossolasco
    Fondazione Matarelli, Ospedale Fatebenefratelli e Oftalmico, Milan, Italy
    Cancer Detect Prev 26:60-3. 2002
    ..The positive cases included 23.6% of the patients with and 9% of those without metastasis. Only 4/60 negative controls analyzed were positive by PCR. Our results show high specificity and a good correlation with disease status...
  63. pmc Limitations of cytokeratin 20 RT-PCR to detect disseminated tumour cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumour tissue
    F A Vlems
    Department of Surgery, University Medical Centre Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Mol Pathol 55:156-63. 2002
    ..The results of this study have been considered in relation to the controversial results in the literature to elucidate the usefulness of cytokeratin 20 (CK20) RT-PCR to detect disseminated tumour cells further...
  64. ncbi Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow
    Markus Maria Heiss
    Department of Surgery, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    J Clin Oncol 20:2005-16. 2002
    ..To study the invasion-related molecule urokinase-type plasminogen activator receptor (u-PAR) expressed by disseminated tumor cells as a biologic predictor of poor survival in a large prospective series of patients with gastric cancer...
  65. ncbi [The influence of the hemoglobin concentration on the hematogenous tumor cell dissemination at the time of the initial diagnosis of breast cancer]
    W Janni
    I Frauenklinik, Klinikum der Ludwig Maximilians Universtität München, Germany
    Dtsch Med Wochenschr 127:71-7. 2002
    ....
  66. ncbi Occult metastases in patients with breast cancer
    D Hawes
    Department of Pathology, Keck School of Medicine at the University of Southern California/Norris Comprehensive Cancer Center, Los Angeles 90033, USA
    Ann Surg Oncol 8:60S-63S. 2001
    ..e., those cells constituting the earliest metastatic population of tumor cells. Thus, techniques that identify occult metastases may be valuable in furthering our understanding of the events regulating tumor dissemination...
  67. ncbi Reverse-transcriptase polymerase chain reaction of the maspin gene in the detection of bone marrow breast carcinoma cell contamination
    A Ballestrero
    Dipartimento di Medicina Interna, , Genova, Italy
    Cancer 92:2030-5. 2001
    ....
  68. ncbi A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma
    H Geminder
    Department of Cell Research and Immunology, George S Wise Faculty of Life Sciences and The Ela Kodesz Institute for Research on Cancer Development and Prevention, Tel Aviv University, Tel Aviv, Israel
    J Immunol 167:4747-57. 2001
    ..Therefore, the ability of neuroblastoma tumors to preferentially form metastases in the bone marrow may be influenced by a set of complex CXCR4-SDF-1 interactions...
  69. ncbi Minimal residual marrow disease: detection and significance of isolated tumour cells in bone marrow
    D G Iorgulescu
    Department of Surgery, University of Melbourne, Geelong Hospital, Victoria, Australia
    ANZ J Surg 71:365-76. 2001
    ....
  70. ncbi Detection of breast cancer cells in the bone marrow or peripheral blood: methods and prognostic significance
    M Lalle
    Istituto di Clinica Ostetrica e Ginecologica, , Rome, Italy
    Tumori 86:183-90. 2000
    ....
  71. ncbi Evaluating GA733-2 mRNA as a marker for the detection of micrometastatic breast cancer in peripheral blood and bone marrow
    X Y Zhong
    Department of Obstetrics and Gynaecology, University Basel
    Arch Gynecol Obstet 263:2-6. 1999
    ..GA733-2 mRNA is not specific as a marker for the detection of breast cancer cells in BM and PB...
  72. ncbi Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients
    Paal Fr Brunsvig
    Cancer Clinic, Rikshospitalet Radiumhospitalet Medical Center, University of Oslo, N 0310 Oslo, Norway
    Lung Cancer 61:170-6. 2008
    ..The clinical relevance of bone marrow micrometastases in non-small cell lung cancer (NSCLC) is undetermined, and the value of such analyses in advanced stage patients has not been assessed previously...
  73. doi Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen
    Christian Schindlbeck
    First Department of Obstetrics and Gynecology, Ludwig Maximilians University of Munich, Munich, Germany
    Clin Exp Metastasis 25:233-40. 2008
    ..Own studies demonstrated a nearly complete TF expression on DTC-BM, indicating its suitability as marker for immunomagnetic enrichment...
  74. pmc Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients
    Mark A Watson
    Department of Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Clin Cancer Res 13:5001-9. 2007
    ....
  75. ncbi Frequency and prognostic relevance of disseminated tumor cells in bone marrow of patients with metastatic renal cell carcinoma
    Alexander Buchner
    Department of Urology, Klinikum Groshadern, Ludwig Maximilians University, Munich, Germany
    Cancer 106:1514-20. 2006
    ....
  76. pmc Limitations in the ability of NB84 to detect metastatic neuroblastoma cells in bone marrow
    S N Bomken
    Department of Paediatric Oncology, Sir James Spence Institute, Royal Victoria Infirmary, Newcastle upon Tyne, UK
    J Clin Pathol 59:927-9. 2006
    ..The accurate assessment of metastases is an essential component of the staging process for children with neuroblastoma...
  77. ncbi Effect of progesterone receptor a predominance on breast cancer cell migration into bone marrow fibroblasts
    E M McGowan
    Westmead Institute for Cancer Research, University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Westmead, NSW, Australia
    Breast Cancer Res Treat 83:211-20. 2004
    ..If borne out in vivo, these findings suggest that tumours with PRA predominance may be predisposed to cancer progression and this may signal a poorer prognosis in patients...
  78. ncbi The molecular detection of micrometastatic breast cancer
    Megan Baker
    Medical University of South Carolina, Department of Surgery, 171 Ashley Ave, Room 420Q CSB, Charleston, SC 29425, USA
    Am J Surg 186:351-8. 2003
    ..Given the controversies concerning application and clinical relevance, this review critically evaluates the current status of these molecular staging technologies...
  79. ncbi Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:3853-8. 2003
    ..To use early marrow response as a prognostic marker is particularly relevant for patients not likely to benefit from this therapy...
  80. ncbi Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy
    Arne Berg
    Faculty of Medicine, University of Oslo, Norway
    Int J Cancer 120:1603-9. 2007
    ..In conclusion our study shows that presence of DTCs in BM at diagnosis was associated with the histological differentiation of the primary tumor and an increased risk of developing distant metastases after RT...
  81. ncbi Molecular biology of leukemia
    Debra Wujcik
    Vanderbilt Ingram Cancer Center, 691 Preston Research Bldg, Nashville, TN 37232 6868, USA
    Semin Oncol Nurs 19:83-9. 2003
    ..To review the current tests for diagnosis and the implications of cytogenetic analysis in leukemia...
  82. ncbi Clinical significance of bone marrow micrometastasis detected by nested rt-PCR for keratin-19 in breast cancer patients
    Yong Sik Jung
    Departments of Surgery, Pathology and Hemato oncology, Ajou University School of Medicine, Suwon, Korea
    Jpn J Clin Oncol 33:167-72. 2003
    ..The aim of this study was to examine the presence of keratin-19 mRNA of epithelial tumors in bone marrow aspirates obtained from breast cancer patients and its possible correlation with tumor staging and disease-free survival...
  83. ncbi Minimal residual disease in bone marrow and peripheral blood of patients with metastatic breast cancer
    Joachim Bischoff
    Department of Gynaecology, Okologische Fachklinik Bad Trissl, 83080 Oberaudorf, Germany
    Recent Results Cancer Res 162:135-40. 2003
    ..The immunocytochemical detection of cytokeratin-positive cells in PB seems to be associated with the site of metastatic manifestation...
  84. ncbi Relevance of disseminated tumour cells in blood and bone marrow of patients with solid epithelial tumours in perspective
    F A Vlems
    Department of Surgery, University Medical Centre Nijmegen, 6500 HB, Nijmegen, The Netherlands
    Eur J Surg Oncol 29:289-302. 2003
    ....
  85. ncbi Detection and clinical relevance of tumor cells in blood and bone marrow of patients with colorectal cancer
    F A Vlems
    Department of Surgery, University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Anticancer Res 23:523-30. 2003
    ..This review describes the advantages and disadvantages of the main detection techniques and discusses the current state of clinical relevance of disseminated tumor cells in patients with colorectal cancer...
  86. ncbi Disseminated tumor cells in bone marrow of patients with transitional cell carcinoma: immunocytochemical detection and correlation with established prognostic indicators
    Thomas Hofmann
    Department of Urology, Klinikum Grosshadern, Luwig Maximilians University of Munich and Staedtisches Krankenhaus Muenchen Bogenhausen, Munich, Germany
    J Urol 169:1303-7. 2003
    ..We evaluated the potential of an immunocytochemical assay, using a monoclonal antibody against cytokeratin 18 (CK 18), for the detection of disseminated tumor cells in bone marrow aspirates of patients with transitional cell carcinoma...
  87. ncbi The stromal composition of mast cell aggregates in systemic mastocytosis
    April Chiu
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    Mod Pathol 22:857-65. 2009
    ..mastocytosis exhibits a distinct pattern of stromal change, and suggest that the fibrogenetic mechanism in systemic mastocytosis is most likely different from that of other bone marrow neoplasms which are also associated with fibrosis.
  88. pmc Engagement of αIIbβ3 (GPIIb/IIIa) with ανβ3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis
    Anke S Lonsdorf
    Department of Dermatology, University Hospital, Ruprecht Karls University Heidelberg, 69115 Heidelberg, Germany
    J Biol Chem 287:2168-78. 2012
    ..Thus, the engagement of GPIIb/IIIa with aνβ3 integrin interaction mediates tumor cell-platelet interactions and highlights how this interaction is involved in hematogenous tumor metastasis...
  89. ncbi Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations
    Anthony J Bench
    Molecular Malignancy Laboratory and Haemato Oncology Diagnostic Service, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, UK
    Br J Haematol 160:25-34. 2013
    ..Molecular results should be considered in the context of clinical findings and other haematological or laboratory results...
  90. ncbi Epithelioid angiosarcoma metastases to the bone marrow manifesting as erythroblastic anemia and leukocytosis: a case report and review of the literature
    Piotr Czapiewski
    Department of Pathology, Medical University of Gdansk, Gdansk, Poland
    Pol J Pathol 63:199-203. 2012
    ..This rare complication of the clinical course of this tumor should be taken into account in the pathological diagnosis of patients with AS presenting with hematological abnormalities...
  91. pmc Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues
    A Vincent-Salomon
    Institut Curie, Paris, France
    J Clin Pathol 61:570-6. 2008
    ..Finally, this review addresses the main biological questions raised by disseminated tumour cells, in particular understanding tumour dormancy and identifying metastatic stem cells...
  92. ncbi Polymerase chain reaction in the diagnosis of T-cell lymphoma in paraffin-embedded bone marrow biopsies: a comparative study
    S Gebhard
    University Institute of Pathology, Lausanne, Switzerland
    Histopathology 38:37-44. 2001
    ..The aim of this study was to evaluate the diagnostic contribution of TCR-gamma gene rearrangement analysed by PCR...
  93. ncbi Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer
    Bjørn Naume
    Cancer Clinic, Rikshospitalet Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway
    Mol Oncol 1:160-71. 2007
    ..This study suggests that DTC in BM differentially distinguishes clinical outcome in patients with luminal A type tumors and that DTC-associated gene expression analysis may identify genes of potential importance in tumor dissemination...
  94. doi Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia
    William G Morice
    Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Mod Pathol 22:807-16. 2009
    ..Apart from this, no other pathological correlates of the clinical or laboratory features of symptomatic Waldenström's macroglobulinemia were identified...
  95. doi Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma
    Tatsuo Kuroda
    Department of Surgery, National Center for Child Health and Development, Tokyo 157 8535, Japan
    J Pediatr Surg 43:2182-5. 2008
    ..The aim of this study was to study the prognostic significance of circulating tumor cells (CTC) and the appropriate indications for aggressive surgery in advanced neuroblastoma...
  96. ncbi Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes
    Kristoph Jahnke
    Department of Hematology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    J Clin Oncol 24:4754-7. 2006
    ....
  97. pmc Increased nm23 immunoreactivity is associated with selective inhibition of systemic tumour cell dissemination
    Alastair N J Graham
    Northern Ireland Regional Department of Thoracic Surgery, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, Northern Ireland
    J Clin Pathol 55:184-9. 2002
    ..The purpose of this study was to investigate whether nm23 selectively influences systemic, pleural, and lymphatic metastasis in non-small cell lung cancer (NSCLC)...
  98. ncbi Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET imaging
    Stephen B Chiang
    Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Nucl Med 28:674-6. 2003
    ..The authors report a patient with diffuse bone marrow involvement of Hodgkin disease that appears indistinguishable from hematopoietic cytokine-mediated FDG bone marrow uptake...
  99. ncbi Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer
    Toshihiro Osaki
    Department of Surgery II, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
    J Clin Oncol 20:2930-6. 2002
    ....
  100. doi Plasmablastic lymphoma affecting the lung and bone marrow with CD10 expression and t(8;14)(q24;q32) translocation
    Khoon Leong Chuah
    Department of Pathology Tan Tock Seng Hospital, Singapore
    Int J Surg Pathol 17:163-6. 2009
    ..In addition, the lymphoma in our case disclosed CD10 positivity on immunohistochemistry and t(8;14)(q24;q34) translocation on cytogenetic analysis, mimicking a Burkitt/atypical Burkitt lymphoma. The problems in diagnosis are discussed...
  101. ncbi Primary bone marrow B-cell lymphoma: report of four cases
    James A Strauchen
    Department of Pathology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mt Sinai J Med 70:133-8. 2003
    ..Diffuse large B-cell lymphoma should be considered in the differential diagnosis of unusual hematologic presentations, particularly in the elderly...

Research Grants79

  1. Molecular Detection of Occult Neuroblastoma
    Irene Cheung; Fiscal Year: 2004
    ..If these two molecular markers of MRD can independently predict patient outcome, they will in the future provide an objective endpoint for stopping further treatment, and serve as sensitive surrogates for evaluating adjuvant therapies. ..
  2. A novel set of molecular markers to measure metastatic neuroblastoma
    Nai Kong Cheung; Fiscal Year: 2007
    ..Armed with the tools to collect samples expeditiously and to measure MRD accurately, the paradigm of treating subclinical NB can then be tested in multicenter randomized studies. [unreadable] [unreadable]..
  3. Beta glucan enhances antibody therapy for neuroblastoma
    Nai Kong Cheung; Fiscal Year: 2003
    ..These findings will have general implications for antibody and vaccine strategies in human cancer models, and the role of polysaccharides as complementary/herbal medicine in immune-based therapies. ..
  4. Cell-based tumor vaccines targeting CD4+ T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2010
    ..Aim 4: Determine if the MHC ll+livaccines produce a novel repertoire of peptides and if ocular melanoma patients'responses are skewed towards the novel peptides. ..
  5. Tumor cell antigen presentation to CD4 + T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2004
    ..of anti-tumor immunity? Which effector cells, cytokines, and chemokines are induced during therapy? 5) Does tumor burden correlate with tumor-induced immuno-suppression? Does surgical removal of primary tumor reverse mmuno-suppression? ..
  6. CELL BASED TUMOR VACCINES TARGETING CD4+ T LUMPHOCYTES
    Suzanne Ostrand Rosenberg; Fiscal Year: 2003
    ..Completion of these studies will provide the framework for conducting a clinical trial, and will provide mechanistic information for further improvement of the vaccines. ..
  7. Tumor cell antigen presentation to CD4 + T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2003
    ..of anti-tumor immunity? Which effector cells, cytokines, and chemokines are induced during therapy? 5) Does tumor burden correlate with tumor-induced immuno-suppression? Does surgical removal of primary tumor reverse mmuno-suppression? ..
  8. CELL BASED TUMOR VACCINES TARGETING CD4+ T LUMPHOCYTES
    Suzanne Ostrand Rosenberg; Fiscal Year: 2002
    ..Completion of these studies will provide the framework for conducting a clinical trial, and will provide mechanistic information for further improvement of the vaccines. ..
  9. Tumor cell antigen presentation to CD4 + T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2002
    ..of anti-tumor immunity? Which effector cells, cytokines, and chemokines are induced during therapy? 5) Does tumor burden correlate with tumor-induced immuno-suppression? Does surgical removal of primary tumor reverse mmuno-suppression? ..
  10. Tumor-induced immune suppression.
    Suzanne Ostrand Rosenberg; Fiscal Year: 2009
    ..abstract_text> ..
  11. Tumor-induced immune suppression
    Suzanne Ostrand Rosenberg; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  12. Tumor-induced immune suppression
    Suzanne Ostrand Rosenberg; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  13. Cell-based tumor vaccines targeting CD4+ T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2007
    ..Aim 4: Determine if the MHC ll+li- vaccines produce a novel repertoire of peptides and if ocular melanoma patients' responses are skewed towards the novel peptides. ..
  14. Tumor-induced immune suppression.
    Suzanne Ostrand Rosenberg; Fiscal Year: 2008
    ..abstract_text> ..
  15. Cell-based tumor vaccines targeting CD4+ T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2008
    ..Aim 4: Determine if the MHC ll+li- vaccines produce a novel repertoire of peptides and if ocular melanoma patients' responses are skewed towards the novel peptides. ..
  16. Cell-based tumor vaccines targeting CD4+ T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2009
    ..Aim 4: Determine if the MHC ll+li- vaccines produce a novel repertoire of peptides and if ocular melanoma patients'responses are skewed towards the novel peptides. ..
  17. Cell-based tumor vaccines targeting CD4+ T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2010
    ..Aim 4: Determine if the MHC ll+li- vaccines produce a novel repertoire of peptides and if ocular melanoma patients'responses are skewed towards the novel peptides. ..
  18. Tumor-induced immune suppression.
    Suzanne Ostrand Rosenberg; Fiscal Year: 2010
    ..abstract_text> ..
  19. Cell-based tumor vaccines targeting CD4+ T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2009
    ..Aim 4: Determine if the MHC ll+li- vaccines produce a novel repertoire of peptides and if ocular melanoma patients'responses are skewed towards the novel peptides. ..
  20. CELL BASED TUMOR VACCINES TARGETING CD4+ T LUMPHOCYTES
    Suzanne Ostrand Rosenberg; Fiscal Year: 2001
    ..Completion of these studies will provide the framework for conducting a clinical trial, and will provide mechanistic information for further improvement of the vaccines. ..
  21. ENHANCING TUMOR IMMUNITY BY CLASS II GENE TRANSFECTION
    Suzanne Ostrand Rosenberg; Fiscal Year: 1990
    ..These studies will establish a mouse model system for testing the potential usefulness of this promising and novel strategy for tumor specific immunotherapy...
  22. CELL BASED TUMOR VACCINES TARGETING CD4+ T LUMPHOCYTES
    Suzanne Ostrand Rosenberg; Fiscal Year: 2000
    ..Completion of these studies will provide the framework for conducting a clinical trial, and will provide mechanistic information for further improvement of the vaccines. ..
  23. ENHANCING TUMOR IMMUNITY BY CLASS II GENE TRANSFECTION
    Suzanne Ostrand Rosenberg; Fiscal Year: 1993
    ..These studies will establish a mouse model system for testing the potential usefulness of this promising and novel strategy for tumor specific immunotherapy...
  24. ENHANCING TUMOR IMMUNITY BY CLASS II GENE TRANSFECTION
    Suzanne Ostrand Rosenberg; Fiscal Year: 1992
    ..These studies will establish a mouse model system for testing the potential usefulness of this promising and novel strategy for tumor specific immunotherapy...
  25. ENHANCING TUMOR IMMUNITY BY CLASS II GENE TRANSFECTION
    Suzanne Ostrand Rosenberg; Fiscal Year: 1991
    ..These studies will establish a mouse model system for testing the potential usefulness of this promising and novel strategy for tumor specific immunotherapy...
  26. ENHANCING TUMOR IMMUNITY BY CLASS II GENE TRANSFECTION
    Suzanne Ostrand Rosenberg; Fiscal Year: 1999
    ..Completion of these studies will therefore provide a strong foundation for future translational research employing this novel immunotherapeutic strategy. ..
  27. ENHANCING TUMOR IMMUNITY BY CLASS II GENE TRANSFECTION
    Suzanne Ostrand Rosenberg; Fiscal Year: 2000
    ..Completion of these studies will therefore provide a strong foundation for future translational research employing this novel immunotherapeutic strategy. ..
  28. Tumor cell antigen presentation to CD4 + T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2001
    ..of anti-tumor immunity? Which effector cells, cytokines, and chemokines are induced during therapy? 5) Does tumor burden correlate with tumor-induced immuno-suppression? Does surgical removal of primary tumor reverse mmuno-suppression? ..
  29. DNA METHYLTRANSFERASE/HISTONE DEACETYLASE INHIBITION
    Steven Gore; Fiscal Year: 2001
    ..This will enable determination of the "molecular response rate" to this therapy and preliminary exploration of correlation between these molecular endpoints and clinical response. ..
  30. Targeting Epigenomics in Myeloid Neoplasms
    Steven Gore; Fiscal Year: 2008
    ..abstract_text> ..
  31. DNA METHYLTRANSFERASE/HISTONE DEACETYLASE INHIBITION
    Steven Gore; Fiscal Year: 2002
    ..This will enable determination of the "molecular response rate" to this therapy and preliminary exploration of correlation between these molecular endpoints and clinical response. ..
  32. DNA METHYLTRANSFERASE/HISTONE DEACETYLASE INHIBITION
    Steven Gore; Fiscal Year: 2000
    ..This will enable determination of the "molecular response rate" to this therapy and preliminary exploration of correlation between these molecular endpoints and clinical response. ..
  33. Arsenic Trioxide in Primary Curative APL Therapy
    Steven Gore; Fiscal Year: 2007
    ..Success of this trial will potentially be followed by the testing of regimen against more conventional and more extensive treatment for APL in a Phase III trial. [unreadable] [unreadable] [unreadable]..
  34. Mechanism of combined 'epigenetic therapy' in myeloid malignancies
    Steven Gore; Fiscal Year: 2008
    ....
  35. Arsenic Trioxide in Primary Curative APL Therapy
    Steven Gore; Fiscal Year: 2006
    ..Success of this trial will potentially be followed by the testing of regimen against more conventional and more extensive treatment for APL in a Phase III trial. [unreadable] [unreadable] [unreadable]..
  36. TARGETING BREAST CANCER WITH SMALL LIGANDS
    David Krag; Fiscal Year: 1999
    ..Specifically, this work will produce lead compounds for drugs with great potential efficacy in the treatment of breast cancer. ..
  37. Proteases in Prostate Cancer Bone Metastasis
    Michael Cher; Fiscal Year: 2007
    ..abstract_text> ..
  38. Bone Marrow Transplant Clinical Network
    Edward Stadtmauer; Fiscal Year: 2007
    ..The focus of this group, in contrast to cancer clinical trials groups, is on improving the transplant procedure per se rather than cancer treatment in general. (End of abstract.) ..
  39. A Novel Long-Lived 41Ca Marker To Assess Bone Turnover For Breast Cancer Patients
    Susanta Hui; Fiscal Year: 2007
    ..These two pursuits will allow physicians to effectively treat high-risk patients early with preventive drugs, and monitor treatments' efficacy, which will improve patients' quality of life and reduce hospital costs. ..
  40. TARGETING BREAST CANCER WITH SMALL LIGANDS
    David Krag; Fiscal Year: 2006
    ..3) Use the structure-based, homologous analog and biased library approach to make educated designs to increase the affinity of the Grb7 ligands ..
  41. The MT1-MMP/RANKL/RANK Axis in Prostate Cancer Bone Metastasis
    Michael Cher; Fiscal Year: 2009
    ..This proposal will use a variety of biochemical and cellular approaches as well as animal models of bone metastasis. ..
  42. Bone Marrow Transplant Clinical Network
    Edward Stadtmauer; Fiscal Year: 2008
    ..The focus of this group, in contrast to cancer clinical trials groups, is on improving the transplant procedure per se rather than cancer treatment in general. (End of abstract.) ..
  43. Physiologic Regulation of Hematopoiesis by Notch
    Nadia Carlesso; Fiscal Year: 2009
    ..The long term goal of this project is to evaluate the role of the Notch signaling pathway both in normal bone marrow reconstitution and in leukemias and to identify novel targets of therapeutic intervention. ..
  44. Physiologic Regulation of Hematopoiesis by Notch
    Nadia Carlesso; Fiscal Year: 2008
    ..The long term goal of this project is to evaluate the role of the Notch signaling pathway both in normal bone marrow reconstitution and in leukemias and to identify novel targets of therapeutic intervention. ..
  45. Sentinel Node Versus Axillary Dissection in Breast Ca.
    David Krag; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  46. Nonablative AlloSCT in Refractory Autoimmune Disease
    Mitchell Cairo; Fiscal Year: 2003
    ....
  47. Physiologic Regulation of Hematopoiesis by Notch
    Nadia Carlesso; Fiscal Year: 2003
    ....
  48. PROSTATE CANCER, BONE METASTASIS, AND METALLOPROTEINASES
    Michael Cher; Fiscal Year: 2003
    ..The results of these studies may lead to new therapeutic strategies aimed at interrupting the interactions between prostate cancer cells and bone. ..
  49. TARGETING BREAST CANCER WITH SMALL LIGANDS
    David Krag; Fiscal Year: 2000
    ..Specifically, this work will produce lead compounds for drugs with great potential efficacy in the treatment of breast cancer. ..
  50. PROSTATE CANCER, BONE METASTASIS, AND METALLOPROTEINASES
    Michael Cher; Fiscal Year: 2000
    ..The results of these studies may lead to new therapeutic strategies aimed at interrupting the interactions between prostate cancer cells and bone. ..
  51. In Vivo Selection of Ligands for Targeted Therapy
    David Krag; Fiscal Year: 2003
    ..Successful completion of this clinical study will result in demonstration of a satisfactory safety profile and short peptides that bind selectively to tumor tissue. ..
  52. Physiologic Regulation of Hematopoiesis by Notch
    Nadia Carlesso; Fiscal Year: 2002
    ....
  53. PROSTATE CANCER, BONE METASTASIS, AND METALLOPROTEINASES
    Michael Cher; Fiscal Year: 2002
    ..The results of these studies may lead to new therapeutic strategies aimed at interrupting the interactions between prostate cancer cells and bone. ..
  54. Physiologic Regulation of Hematopoiesis by Notch
    Nadia Carlesso; Fiscal Year: 2001
    ....
  55. TARGETING BREAST CANCER WITH SMALL LIGANDS
    David Krag; Fiscal Year: 2001
    ..Specifically, this work will produce lead compounds for drugs with great potential efficacy in the treatment of breast cancer. ..
  56. First Int'l Symposium on Childhood and Adolescent NHL
    Mitchell Cairo; Fiscal Year: 2003
    ..abstract_text> ..
  57. PROSTATE CANCER, BONE METASTASIS, AND METALLOPROTEINASES
    Michael Cher; Fiscal Year: 2004
    ..The results of these studies may lead to new therapeutic strategies aimed at interrupting the interactions between prostate cancer cells and bone. ..
  58. Targeted Enzymes for Prodrug Therapy
    David Krag; Fiscal Year: 2006
    ..Successful completion of these experiments will result in demonstration of novel targeted effector molecules that bind selectively to tumors and activate cytotoxic prodrugs. ..
  59. Sentinel Node Versus Axillary Dissection in Breast Ca.
    David Krag; Fiscal Year: 2005
    ....
  60. Targeted Enzymes for Prodrug Therapy
    David Krag; Fiscal Year: 2007
    ..Successful completion of these experiments will result in demonstration of novel targeted effector molecules that bind selectively to tumors and activate cytotoxic prodrugs. ..
  61. Proteases in Prostate Cancer Bone Metastasis
    Michael Cher; Fiscal Year: 2004
    ..abstract_text> ..
  62. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2004
    ..Analogous to our work with Muc-1, we will also attempt to identify other PCD selective targets by generating and examining mAbs specific to the plasma cell glycoform of CD138. ..
  63. Physiologic Regulation of Hematopoiesis by Notch
    Nadia Carlesso; Fiscal Year: 2010
    ..The long term goal of this project is to evaluate the role of the Notch signaling pathway both in normal bone marrow reconstitution and in leukemias and to identify novel targets of therapeutic intervention. ..
  64. Sentinel Node Versus Axillary Dissection in Breast Cancer
    David Krag; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  65. Sentinel Node Versus Axillary Dissection in Breast Cancer
    David N Krag; Fiscal Year: 2010
    ....
  66. Physiologic Regulation of Hematopoiesis by Notch
    Nadia Carlesso; Fiscal Year: 2004
    ....
  67. Targeted Enzymes for Prodrug Therapy
    David Krag; Fiscal Year: 2005
    ..Successful completion of these experiments will result in demonstration of novel targeted effector molecules that bind selectively to tumors and activate cytotoxic prodrugs. ..
  68. TARGETING BREAST CANCER WITH SMALL LIGANDS
    David Krag; Fiscal Year: 2004
    ..3) Use the structure-based, homologous analog and biased library approach to make educated designs to increase the affinity of the Grb7 ligands ..
  69. TARGETING BREAST CANCER WITH SMALL LIGANDS
    David Krag; Fiscal Year: 2005
    ..3) Use the structure-based, homologous analog and biased library approach to make educated designs to increase the affinity of the Grb7 ligands ..
  70. A Novel Long-Lived 41Ca Marker To Assess Bone Turnover For Breast Cancer Patients
    Susanta Hui; Fiscal Year: 2008
    ..These two pursuits will allow physicians to effectively treat high-risk patients early with preventive drugs, and monitor treatments' efficacy, which will improve patients' quality of life and reduce hospital costs. ..
  71. Sentinel Node Versus Axillary Dissection in Breast Cancer
    David Krag; Fiscal Year: 2009
    ....